Acute Effects of Blood Pressure Elevation on Insulin Clearance in Normotensive Healthy Subjects

Hypertension

Volumn 31, Issue 1, 1998, Pages 104-109

  O'Callaghan, Christopher J ^a   Komersova, Karla ^a   Louis, William J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; ISOPRENALINE; PHENYLEPHRINE;

ADULT; ALPHA ADRENERGIC STIMULATION; ARTICLE; BETA ADRENERGIC STIMULATION; DISEASE ASSOCIATION; GLUCOSE UTILIZATION; HUMAN; HUMAN EXPERIMENT; HYPERINSULINEMIA; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN CLEARANCE; INSULIN SENSITIVITY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC BETA-AGONISTS; ADULT; ANGIOTENSIN II; BLOOD GLUCOSE; BLOOD PRESSURE; DOUBLE-BLIND METHOD; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPERINSULINISM; INSULIN; ISOPROTERENOL; MALE; METABOLIC CLEARANCE RATE; PHENYLEPHRINE;

EID: 0031952641     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/01.HYP.31.1.104     Document Type: Article

References (42)

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.
2. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S. Insulin resistance in essential hypertension. N Engl J Med. 1987;317:350-357.
3. Reaven GM, Lerner RL, Stern MP, Farquhar JW. Role of insulin in endogenous hypertriglyceridemia. J Clin Invest. 1967;46:1756-1767.
4. Rocchini AP, Katch V, Kveselis D, Moorehead C, Martin M, Lampman R, Gregory M. Insulin and renal sodium retention in obese adolescents. Hypertension. 1989;14:367-374.
5. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996;334:374-381.
6. Stout RW, Bierman EL, Ross R. Effect of insulin on the proliferation of cultured primate arterial smooth muscle cells. Circ Res. 1975;36:319-327.
7. Shinozaki K, Suzuki M, Ikebuchi M, Takaki H, Hara Y, Tsushima M, Harano Y. Insulin-resistance associated with compensatory hyperinsulinemia as an independent risk factor for vasospastic angina. Circulation. 1995;92:1749-1757.
8. Suzuki M, Shinozaki K, Kanazawa A, Hara Y, Hattori Y, Tsushima M, Harano Y. Insulin-resistance as an independent risk factor for carotid wall thickening. Hypertension. 1996;28:593-598.
9. Welborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care. 1979;2:154-160.
10. Giugliano D, Salvatore T, Paolisso G, Buoninconti R, Torella R, Varricchio M, D'Onofrio F. Impaired glucose metabolism and reduced insulin clearance in elderly hypertensives. Am J Hypertens. 1992;5:345-353.
11. Salvatore T, Cozzolino D, Giunta R, Giugliano D, Torella R, D'Onofrio F. Decreased insulin clearance as a feature of essential hypertension. J Clin Endocrinol Metab. 1992;74:144-149.
12. Sheu WH, Jeng CY, Shieh SM, Fuh MM. Hepatic insulin extraction and insulin clearance in patients with essential hypertension. Clin Exp Hypertens. 1994;16:691-707.
13. Swislocki AL. Impaired insulin clearance in essential hypertension. J Hum Hypertens. 1994;8:185-190.
14. Lender D, Arauz-Pacheco C, Adams-Huet B, Raskin PR. Essential hypertension is associated with decreased insulin clearance and insulin resistance. Hypertension. 1997;29:111-114.
15. Eaton RP, Friedman N, Allen RC, Schade DS. Insulin removal in man: in vivo evidence for a receptor-mediated process. J Clin Endocrinol Metab. 1984;58:555-559.
16. Tillil H, Shapiro ET, Rubenstein AH, Galloway JA, Polonsky KS. Reduction of insulin clearance during hyperglycemic clamp: dose-response study in normal humans. Diabetes. 1988;37:1351-1357.
17. Mark AL. The sympathetic nervous system in hypertension: a potential long-term regulator of arterial pressure. J Hypertens. 1996;S159-S165.
18. Meier A, Weidmann P, Grimm M, Keusch G, Gluck Z, Minder I, Ziegler WH. Pressor factors and cardiovascular pressor responsiveness in borderline hypertension. Hypertension. 1981;3:367-372.
19. Deibert DC, DeFronzo RA. Epinephrine-induced insulin resistance in man. J Clin Invest. 1980;65:717-721.
20. Pollare T, Lithell H, Selinus I, Berne C. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia. 1988;31:415-420.
21. Pollare T, Lithell H, Morlin C, Prantare H, Hvarfner A, Ljunghall S. Metabolic effects of diltiazem and atenolol: results from a randomized, double-blind study with parallel groups. J Hypertens. 1989;7:551-559.
22. Buchanan TA, Thawani H, Kades W, Modrall JG, Weaver FA, Laurel C, Poppiti R, Xiang A, Hsueh W. Angiotensin II increases glucose utilization during acute hyperinsulinemia via a hemodynamic mechanism. J Clin Invest. 1993;92:720-726.
23. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Eng J Med. 1989;321:868-873.
24. Lager I, Attvall S, Eriksson BM, von Schenk H, Smith U. Studies on the insulin-antagonistic effect of catecholamines in normal man. Evidence for the importance of beta 2-receptors. Diabetologia. 1986;29:409-416.
25. Castillo MJ, Scheen AJ, Letiexhe MR, Lefebvre PJ. How to measure insulin clearance. Diabetes Metab Rev. 1994;10:119-150.
26. Doberne L, Greenfield MS, Schulz B, Reaven GM. Enhanced glucose utilization during prolonged glucose clamp studies. Diabetes. 1981;30:829-835.
27. Polonsky KS, Rubenstein AH. C-peptide as a measure of the secretion and hepatic extraction of insulin: pitfalls and limitations. Diabetes. 1984;33:486-494.
28. O'Callaghan CJ. Essential hypertension is associated with decreased insulin clearance and insulin resistance. Hypertension. In press. Letter.
29. Bos WJW, van den Meirackar AH, Wesseling KH, Schalekamp ADH. Effect of regional and systemic changes in vasomotor tone on finger pressure amplification. Hypertension. 1995;26:315-320.
30. Fink RI, Revers RR, Kolterman OG, Olefsky JM. The metabolic clearance of insulin and the feedback inhibition of insulin secretion are altered with aging. Diabetes. 1985;34:275-280.
31. Rasmussen H, Zawalich KC, Ganesan S, Calle R, Zawalich WS. Physiology and pathophysiology of insulin secretion. Diabetes Care. 1990;13:655-666.
32. Ferrannini E, Wahren J, Faber OK, Felig P, Binder C, DeFronzo RA. Splanchnic and renal metabolism of insulin in human subjects: a dose-response study. Am J Physiol. 1983;244:E517-E527.
33. Grahame-Smith DG, Aronsen JK. Oxford Textbook of Clinical Pharmacology and Drug Therapy. Oxford, UK: Oxford University Press; 1992:44-45.
34. Richardson PD, Withrington PG. Liver blood flow. II. Effects of drugs and hormones on liver blood flow. Gastroenterology. 1981;81:356-375.
35. Goldstein BJ, Kahn CR. Insulin receptors in the normal and disease states. In: Alberti G, ed. International Textbook of Diabetes Mellitus. Chichester, UK: John Wiley & Sons Ltd; 1992:357-375.
36. Desoye G, Ertl-Stockinger U, Porta S. Prolonged administration in vivo of alpha and beta adrenergic agonists decreases insulin binding to rat myocardial membranes in vitro by different mechanisms. Life Sci. 1991;48:2249-2258.
37. Kawai T, Powell A, Arinze IJ. Adrenergic receptors in human liver plasma membranes: predominance of beta2 and alpha1 receptor subtypes. J Clin Endocrinol Metab. 1986;62:827-832.
38. Rosen OM. After insulin binds. Science. 1987;237:1452-1458.
39. Smet G, Hoobler SW, Sanbar S, Julis S. Clinical observations on a new antihypertensive drug, 2-(2,6-dichlorphenylamine)-2-imidazoline hydrochloride. Am Heart J. 1969;77:473-478.
40. Leclercq-Meyer V, Herchuelz A, Valverde I, Couturier E, Marchand J, Malaisse WJ. Mode of action of clonidine upon islet function: dissociated effects upon the time course and magnitude of insulin release. Diabetes. 1980;29:193-200.
41. Hosker JP, Rudenski AS, Burnett MA, Matthews DR, Turner RC. Similar reduction of first- and second-phase B-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy. Diabetalogia. 1989;38:767-772.
42. Ganrot PO. Insulin resistance syndrome: possible key role of blood flow in resting muscle. Diabetalogia. 1993;36:876-879.